VERTEX PHARMACEUTICALS INC / MA (VRTX)
VERTEX PHARMACEUTICALS INC / MA (VRTX) from its SEC filings: 2025 revenue $12.0 billion (+9% vs the year before), net margin 33%, free cash flow $3.2 billion. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $12.0 billion |
| Revenue growth | +9% |
| Net income | $4.0 billion |
| Net margin | 32.9% |
| Free cash flow | $3.2 billion |
| Diluted EPS | $15.32 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +12% |
| Cash | $6.1 billion |
| Long-term debt | $105.0 million |
| Share count, 1 year | -1% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.